DYRKi

DYRKi is an inhibitor of DYRK1 and DYRK1B with IC50 values of 3.7 µM and 90 nM, respectively, which is used as a potent antagonist of Hh/Gli signaling. DYRKi impairs SMO-dependent and SMO-independent oncogenic GLI activity in human medulloblastoma cells. DYRKi is promising for research of HH/GLI-associated cancers .


Cat. No.: EX-A11381	Purity: >98%

	Chemical structure of DYRKi

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	get quote	Inquire
250mg	get quote	Inquire
500mg	get quote	Inquire
1g	get quote	Inquire
2g	get quote	Inquire
5g	get quote	Inquire

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	1640364-04-0
Purity	>98%
Formula	C20H13F3N4O2S
Mol Weight	430.403
State	solid
Shelf Life	>3 years if stored properly
Storage	Powder 4℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Kokkorakis N, et al. Mirk/Dyrk1B Kinase Inhibitors in Targeted Cancer Therapy. Pharmaceutics. 2024 Apr 11;16(4):528. [2]. Gruber W, et al. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance. Oncotarget. 2016 Feb 9;7(6):7134-48.
CoA	CoA of DYRKi

Smiles:	O=C(NC1=NC2=CC(C(F)(F)F)=CC=C2N1)C3=CSC(C4=CC=C5OCCC5=C4)=N3


		Search